Loading clinical trials...
Loading clinical trials...
Feasibility Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid: A Pilot Randomized Control Trial
Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.
This study is a prospective, open-label, single-blind, randomized control study. Study duration is approximately 6 weeks starting at the baseline visit. We will recruit 30 participants (15 per arm) for this pilot study.
Age
20 - 65 years
Sex
ALL
Healthy Volunteers
No
UT Southwestern Medical Center
Dallas, Texas, United States
Start Date
June 1, 2025
Primary Completion Date
September 1, 2025
Completion Date
October 1, 2025
Last Updated
August 26, 2025
Amantadine
DRUG
Physical, Occupational, Speech Therapy
OTHER
Provider Counseling
OTHER
Medications for symptoms management
OTHER
Lead Sponsor
University of Texas Southwestern Medical Center
NCT06721949
NCT06631287
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06086366